News
-
An online survey of 205 pulmonologists and pulmonology fellows conducted by the American Thoracic Society and Sunovion Pharmaceuticals has found that two thirds of the physicians believe that hand-held nebulizers are superior to both MDIs… Read more . . .
-
The US Department of Health and Human Services (HHS) has announced that its Biomedical Advanced Research and Development Authority (BARDA) has issued a $10.49 million task order to the Centers for Innovation in Advanced Development… Read more . . .
-
CRO Aptuit has acquired preclinical formulation specialist Kuecept Ltd, the company said. Both companies have extensive experience in respiratory drug delivery. Kuecept Founder and CEO Mark Saunders commented, “Since our inception in 2007, we have… Read more . . .
-
Grupo Ferrer will acquire inhaled drug developer Alexza Pharmaceuticals for $0.90 per share in a deal that is expected to be completed by mid-2016, the two companies have announced. In February 2016, Alexza announced that… Read more . . .
-
Submission for podium and poster presentations are due by July 29, 2016. Areas of particular interest for DDL27 include: • Inhalers – were they really meant for humans? • Beyond Asthma and COPD • 60… Read more . . .
-
Submit workshop proposals by June 16, 2016 at http://www.rddonline.com/rdd/workshop_reg.php?id=14&sid=6. Podium abstract submissions accepted until August 1, 2016 at http://www.rddonline.com/rdd/speaker_reg.php?id=14. Scientific poster abstract submissions will be due by January 6, 2017. Read more . . .
-
Marina Biotech will pay up to $95 million in milestone payments, plus a “mid-single digit” royalty, in addition to 53 million Marina common shares to acquire Turing Pharmaceutical’s intranasal ketamine program, including all existing product,… Read more . . .
-
Catalent Pharma Solutions. As a member of the inhalation development team, you will utilize your expertise to support the advancement of a variety of pulmonary dosage forms that include pMDIs, DPIs, nasal sprays and solutions/suspensions… Read more . . .
-
On the first morning of RDD 2016, Peter Byron welcomed over 600 OINDP specialists from approximately 30 different countries to this year’s meeting, which offered an optimistic vision of the future of inhaled and nasal… Read more . . .
-
An EMA Pharmacovigilance Risk Assessment Committee (PRAC) review of published data from controlled clinical trials, observational studies, and meta-analyses has concluded that all inhaled corticosteroid (ICS) products appear to carry a similar risk of pneumonia… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
No events are found.